Table 1

Summary of clinical trials on developmental therapeutics

Abstract ID	Abstract type	Study design	Study name and/or ID	Target or biomarker	Intervention	Preliminary results
Abstracts presented at ASCO23
LBA55075	Oral abstract session	Phase III	MIRASOL; GOG 3045/ENGOT-ov55; NCT04209855	FR-α	Mirvetuximab soravtansine vs investigator’s choice of chemotherapy	This antibody–drug conjugate improved progression-free survival and overall survival in platinum-resistant ovarian cancer compared with single agents (paclitaxel, pegylated liposomal doxorubicin, or topotecan)
55057	Oral abstract session	Phase III	OVAL Study/GOG 3018; NCT03398655	FasR/ TNFR1	Ofranergene obadenovec combined with paclitaxel vs paclitaxel with placebo	The combination of ofranergene obadenovec to paclitaxel did not improve progression-free survival or overall survival
TPS56128	Poster session	Phase III (study protocol)	ARTISTRY-7; GOG-3063; ENGOT-OV68; NCT05092360	CD8+ T cells and natural killers	Nemvaleukin and/or pembrolizumab vs chemotherapy	The study will randomize 376 patients to receive nemvaleukin α as a combination therapy with pembrolizumab compared with investigator’s choice chemotherapy This trial is currently recruiting patients, and it has an estimated primary completion date in December 2025
55089	Oral abstract session	Phase I	STRO-002-GM1; NCT03748186	FR-α	Luveltamab tazevibulin	Progression-free survival and objective response rate in RECIST-evaluable patients of this dose expansion cohort (FolRα intensity expression >25%) were 6.1 months and 37.5%, respectively Emerging treatment adverse events led to dose reduction in 61% of enrolled patients Most common grade ≥3 adverse events were neutropenia (70.5%), arthralgia (18.2%), and anemia (13.6%)
e1755210	Publication only	Phase II	CC-ANNIE; NCT05130515	PARP/ VEGFR	Niraparib and anlotinib combination	This study did not meet the primary efficacy endpoint This combination did not show activity in patients with platinum-resistant clear cell histotype
551211	Poster session	Phase II	NCI-9944; NCT02595892	ATR	Berzosertib and gemcitabine vs gemcitabine	Combination of gemcitabine/berzosertib did not significantly improve overall survival vs gemcitabine alone Overall survival benefits were observed in patients harboring low replication stress alterations
557412	Poster session	Phase I	NCT03246074	Syk	Fostamatinib combined with weekly paclitaxel	This combination showed signals of efficacy including partial and complete responses (39%)
554413	Poster session	Phase I	NCT04406623	CD47	SL-172154 (SIRPα-Fc-CD40L)	This first-in-human drug was well tolerated, and best reported response was stable disease in 6 of 27 evaluable patients
559014	Poster session	Phase I	NCT03907527	–	PRGN-3005 autologous UltraCAR-T	This CART cell-based therapy was well tolerated and provided encouraging disease control rates
TPS561715	Poster session	Phase II (study protocol)	NCT04918186	–	CRI-CCTG-0003/ IND.240 immunotherapy platform (IPROC)	This adaptive platform trial was designed to evaluate various combinations of immune-checkpoint inhibitors and antibody-drug conjugates accommodated by both biomarker-agnostic and biomarker-directed selection The estimated primary completion date of this trial is June 2024, and it is currently recruiting platinum-resistant ovarian cancer patients
TPS561616	Poster session	Phase I/II (study protocol)	NCT05538624	IL-2	AVB-001	This first-in-human study investigating this encapsulated cell product engineered to produce native human interleukin-2 to be delivered intraperitoneally is currently recruiting patients It is expected to enroll 44* platinum-resistant ovarian cancer patients and it is estimated to be completed in August 2026
301217	Poster session	Phase I	Debio 0123–101; NCT03968653	WEE1	Debio 0123	This ATP-competitive WEE1 inhibitor combined with carboplatin was well tolerated and it was found to be effective with confirmed partial responses in 4 of 12 evaluable PROC patients
555418	Poster session	Phase I	NCT04329494	–	Pressurized intraperitoneal aerosolized chemotherapy (PIPAC)	PIPAC using cisplatin/doxorubicin in platinum-resistant ovarian cancer showed intraperitoneal responses in patients with low-grade serous carcinoma patients Heavily pretreated and high grade platinum-resistant ovarian cancer derived limited intraperitoneal control
Abstracts presented at ESMO23
747O19	Oral abstract session	Phase II	BOUQUET; NCT04931342	MEK1/ PD-L1-VEGF	Cobimetinib or atezolizumab +bevacizumab	Patients who received ≥3 prior lines of treatment had a 16% confirmed objective response rate with cobimetinib and 14% with the combination
753P20	Poster session	Phase Ib	NCT05551507	FAK	IN10018+pegylated liposomal doxorubicin	No grade 4 or 5 adverse events related to IN10018 were reported Objective response rate was 46.3%, median progression-free survival was 7.3 months and median overall survival was 20.9 months in all treated patient populations
746MO21	Oral abstract session	Phase II	NCT04739800; NRG-GY023	PARP-VEGFR -PD-L1	Durvalumab+olaparib+ cediranib/ olaparib+cediranib/ durvalumab+cediranib/ standard of care chemotherapy	None of the experimental combinations improved progression-free survival compared with chemotherapy in heavily pretreated platinum-resistant ovarian cancer
745MO22	Oral abstract session	Phase I	NCT04707248	Cadherin 6	Raludotatug deruxtecan	Adverse events of grade ≥3 were observed in 50% of the study population, and 38% of the enrolled patients exhibited a response, including one complete response

*Based on clinical trial record on clinicaltrials.gov database.
ATR, ataxia telangiectasia and Rad3-related protein; CART, chimeric antigen receptor T cells; FAK, focal adhesion kinase; FR-α, folate receptor α; IL, interleukin; IPROC, Immunotherapy platform study in platinum-resistant high grade serous ovarian cancer; PARP, poly-ADP ribose polymerase; PD-L1, programmed cell death ligand 1; PIPAC, pressurized intraperitoneal aerosolized chemotherapy; PROC, platinum-resistant ovarian cancer; RECIST, Response Evaluation Criteria in Solid Tumors; TNFR1, tumor necrosis factor receptor 1; VEGF, vascular endothelial growth factor.